Local injections of the corticosteroid dexamethasone alleviated symptoms and resulted in complete remission in most patients with ocular myasthenia gravis, a small clinical trial has shown. Compared to systemic treatments, local injections treated symptoms faster, reduced side effects, and increased remission rate.
News
An analysis of the thymuses removed from people with myasthenia gravis (MG) found lower levels of micro RNA molecules (miRNAs) that may contribute to disease development by favoring increased production of pro-inflammatory proteins and cells, a study suggests. …
Argenx is looking for participants in an app-based international study of the impact and burden of myasthenia gravis (MG) on patients and their families. The company has released an app called MyRealWorld MG to gather information about individuals’ diagnosis, complications, treatments, activities, and quality of life, using…
A photo of a bespectacled young boy, his red baseball cap slightly askew as he enjoys time outside, will be featured on the front cover of an upcoming calendar in the “Same But Different” contest to raise awareness about rare disorders. “A Lovely Day Out in Kew Gardens,” the…
A Japanese man with generalized myasthenia gravis (gMG) experienced a severe worsening of symptoms after discontinuing treatment with Soliris (eculizumab), a case study reported. Titled “Severe worsening of myasthenic symptoms after…
Activating the bile acid receptor TGR5 was found to reduce the number of immune cells that secrete proinflammatory proteins, suggesting that this receptor may be a therapeutic target for people with myasthenia gravis (MG), a study reported. The study, “…
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like the option of continuing its use in future appointments, a series of surveys found. The surveys were conducted by the National Organization for Rare Disorders (NORD) and involved more than 800…
The first published case of a person developing ocular myasthenia gravis (MG) secondary to COVID-19 was described in a new report. The patient, a 65-year-old woman with a medical history of kidney cancer, pituitary tumor, and a blockage in the pulmonary artery in the lungs, ultimately was successfully…
The first participant has been dosed in a Phase 1/2a trial evaluating NMD670, NMD Pharma‘s investigational therapy for myasthenia gravis (MG). “I am pleased to announce that our lead program has entered the clinic. NMD670 has already shown great promise in preclinical studies and…
Treatment with Argenx‘s investigational therapy efgartigimod leads to significant and early reductions in the severity of generalized myasthenia gravis (gMG), regardless of the presence of antibodies against acetylcholine receptor (AChR), according to results from a Phase 3 clinical trial. Trial findings were presented earlier this month at…
Recent Posts
- Reflecting on decades of rich history that led to our modern MG treatments
- Immune system activity varies across MG subtypes, study finds
- Treatment eases gMG symptoms, cuts need for corticosteroid use
- In our marriage, we say no to start a conversation, not end one
- Combining different treatment philosophies in my life with MG